BG
VRTX icon

BlackRock Group’s Vertex Pharmaceuticals VRTX Stock Holding History

BlackRock Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$219M Buy
2,967,665
+574,087
+24% +$46.7M 0.1% 231
2016
Q3 		$209M Buy
2,393,578
+57,835
+2% +$5.47M 0.11% 228
2016
Q2 		$201M Buy
2,335,743
+203,062
+10% +$17.5M 0.1% 238
2016
Q1 		$170M Sell
2,132,681
-18,268
-0.8% -$1.65M 0.09% 266
2015
Q4 		$271M Sell
2,150,949
-32,477
-1% -$3.92M 0.15% 155
2015
Q3 		$227M Sell
2,183,426
-276,580
-11% -$35.5M 0.13% 180
2015
Q2 		$304M Buy
2,460,006
+5,899
+0.2% +$743K 0.17% 142
2015
Q1 		$290M Sell
2,454,107
-11,645
-0.5% -$1.4M 0.16% 147
2014
Q4 		$293M Buy
2,465,752
+274,439
+13% +$30.9M 0.16% 145
2014
Q3 		$246M Buy
2,191,313
+164,212
+8% +$15.6M 0.14% 159
2014
Q2 		$192M Sell
2,027,101
-2,225
-0.1% -$156K 0.11% 223
2014
Q1 		$144M Buy
2,029,326
+11,177
+0.6% +$885K 0.09% 251
2013
Q4 		$150M Sell
2,018,149
-18,746
-0.9% -$1.31M 0.1% 238
2013
Q3 		$154M Buy
2,036,895
+652,783
+47% +$51.9M 0.1% 221
2013
Q2 		$111M Buy
+1,384,112
New +$102M 0.08% 267

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Group's VRTX Position: Q4 2016 in Review

BlackRock Group increased its Vertex Pharmaceuticals (VRTX) stake by 24% in Q4 2016, buying an estimated $46.7M and bringing the position to 2,967,665 shares worth $219M. The position accounts for 0.1% of the portfolio, ranked #231.

BlackRock Group first reported a position in VRTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $304M in Q2 2015. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

  • BlackRock Group held 2,967,665 shares of Vertex Pharmaceuticals worth $219M as of Q4 2016.
  • BlackRock Group bought 574,087 Vertex Pharmaceuticals shares in Q4 2016, an estimated $46.7M.
  • Vertex Pharmaceuticals made up 0.1% of BlackRock Group's portfolio in Q4 2016, its #231 holding.
  • BlackRock Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Vertex Pharmaceuticals position peaked at $304M in Q2 2015.
  • 483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.